This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Investigators from South Korea conducted a randomized, double-blind, placebo-controlled noninferiority trial to compare the efficacy of oral ibuprofen versus placebo for patent ductus arteriosus (PDA) in reducing incidence of death or bronchopulmonary dysplasia (BPD). Infants were eligible if they were: (a) born at the study institution at a gestational age of 23–30 weeks, (b) required respiratory support, and (c) had a PDA that was >1.5 mm with predominant left-to-right flow. Demographics and clinical characteristics of participants were collected at enrollment.
Participants were randomized to receive either oral ibuprofen (administered within 24 hours of randomization with an initial dose of 10 mg/kg and followed by two 5 mg/kg doses 24 and 48 hours later) or placebo (normal saline administered with …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.